Latest & greatest articles for dabigatran

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dabigatran or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dabigatran and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dabigatran

21. Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation. Full Text available with Trip Pro

Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation. The risk of osteoporotic fracture with dabigatran use in patients with nonvalvular atrial fibrillation (NVAF) is unknown.To investigate the risk of osteoporotic fracture with dabigatran vs warfarin in patients with NVAF.Retrospective cohort study using a population-wide database managed by the Hong Kong Hospital Authority. Patients newly diagnosed with NVAF from (...) 2010 through 2014 and prescribed dabigatran or warfarin were matched by propensity score at a 1:2 ratio with follow-up until July 31, 2016.Dabigatran or warfarin use during the study period.Risk of osteoporotic hip fracture and vertebral fracture was compared between dabigatran and warfarin users using Poisson regression. The corresponding incidence rate ratio (IRR) and absolute risk difference (ARD) with 95% CIs were calculated.Among 51 496 patients newly diagnosed with NVAF, 8152 new users

2017 JAMA

22. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. Full Text available with Trip Pro

Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. Catheter ablation of atrial fibrillation is typically performed with uninterrupted anticoagulation with warfarin or interrupted non-vitamin K antagonist oral anticoagulant therapy. Uninterrupted anticoagulation with a non-vitamin K antagonist oral anticoagulant, such as dabigatran, may be safer; however, controlled data are lacking. We investigated the safety of uninterrupted dabigatran versus warfarin in patients (...) undergoing ablation of atrial fibrillation.In this randomized, open-label, multicenter, controlled trial with blinded adjudicated end-point assessments, we randomly assigned patients scheduled for catheter ablation of paroxysmal or persistent atrial fibrillation to receive either dabigatran (150 mg twice daily) or warfarin (target international normalized ratio, 2.0 to 3.0). Ablation was performed after 4 to 8 weeks of uninterrupted anticoagulation, which was continued during and for 8 weeks after

2017 NEJM Controlled trial quality: predicted high

23. Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines

Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines | CADTH.ca Find the information you need Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines (...) Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines Published on: January 31, 2017 Project Number: RD0035-000 Product Line: Research Type: Drug Report Type: Peer-reviewed summary with critical appraisal Result type: Report Question What is the comparative effectiveness and safety of idarucizumab versus standard supportive care for reversing the anticoagulation state in adults treated with dabigatran

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

24. Intravenous thrombolysis in ischaemic stroke after dabigatran reversal by idarucizumab: review of literature

Intravenous thrombolysis in ischaemic stroke after dabigatran reversal by idarucizumab: review of literature Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2017 PROSPERO

25. Dabigatran for thromboembolic prophylaxis in atrial fibrillation: Evidence profile

Dabigatran for thromboembolic prophylaxis in atrial fibrillation: Evidence profile

2017 DynaMed Plus

26. Cohort study: Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation

Cohort study: Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation Article

2017 Evidence-Based Medicine

27. Anticoagulant: the "antidote" to dabigatran (Pradaxa) is insufficiently evaluated

Anticoagulant: the "antidote" to dabigatran (Pradaxa) is insufficiently evaluated Prescrire IN ENGLISH - Spotlight ''Anticoagulant: the "antidote" to dabigatran (Pradaxa°) is insufficiently evaluated'', 1 November 2016 {1} {1} {1} | | > > > Anticoagulant: the "antidote" to dabigatran (Pradaxa°) is insufficiently evaluated Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |  (...)  |  Spotlight Anticoagulant: the "antidote" to dabigatran (Pradaxa°) is insufficiently evaluated The effects of idarucizumab (Praxbind°) have not been sufficiently evaluated: its effect against the risk of bleeding is not proven. Its authorisation as an antidote should not encourage the wider use of dabigatran. When it is necessary to thin the blood with an oral anticoagulant, warfarin, a vitamin K antagonist, is the reference treatment. Dabigatran (Pradaxa°), an anticoagulant from

2016 Prescrire

28. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States Full Text available with Trip Pro

Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States Limited data are available about the real-world safety of non-vitamin K antagonist oral anticoagulants (NOACs).To compare the major bleeding risk among newly anticoagulated non-valvular atrial fibrillation (NVAF) patients initiating apixaban, warfarin, dabigatran or rivaroxaban in the United States.A retrospective (...) cohort study was conducted to compare the major bleeding risk among newly anticoagulated NVAF patients initiating warfarin, apixaban, dabigatran or rivaroxaban. The study used the Truven MarketScan(®) Commercial & Medicare supplemental US database from 1 January 2013 through 31 December 2013. Major bleeding was defined as bleeding requiring hospitalisation. Cox model estimated hazard ratios (HRs) of major bleeding were adjusted for age, gender, baseline comorbidities and co-medications. Among 29 338

2016 EvidenceUpdates

29. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II Full Text available with Trip Pro

Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II Dabigatran was non-inferior to warfarin for prevention of recurrent venous thromboembolism (VTE), and dabigatran had a lower rate of bleeding compared with warfarin in two large-scale randomised trials, RE-COVER and RE-COVER II. In this study, we investigate the efficacy and safety of dabigatran versus warfarin according to the index event that qualified the patient (...) for enrollment, either symptomatic pulmonary embolism (PE) with or without deep-vein thrombosis (DVT), or DVT alone. We then analyse the anticoagulant effect of dabigatran vs warfarin on patients enrolled with PE. The pooled dataset for the efficacy analysis consisted of 2553 and 2554 patients who were randomised to dabigatran and warfarin, respectively. Recurrent VTE/VTE-related death during the study period and additional 30-day follow-up occurred in 2.7 % of all patients on dabigatran and in 2.4

2016 EvidenceUpdates Controlled trial quality: uncertain

30. Reversal of the anticoagulant effect of dabigatran: idarucizumab

Reversal of the anticoagulant effect of dabigatran: idarucizumab Re Rev versal of the anticoagulant effect of ersal of the anticoagulant effect of dabigatr dabigatran: idarucizumab an: idarucizumab Evidence summary Published: 24 May 2016 nice.org.uk/guidance/esnm73 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in May 2016. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA (...) or NICE websites for up- to-date information. Summary Idarucizumab is the first agent to be licensed in the UK that reverses the anticoagulant effect of a non-vitamin K antagonist oral anticoagulant (NOAC). Its action is specific against the NOAC dabigatran etexilate. In the interim analysis of an ongoing, phase III, uncontrolled, cohort study (RE-VERSE AD; n=90), treatment with a 5 g dose of idarucizumab completely reversed the anticoagulant effect of dabigatran etexilate in adults who had either

2016 National Institute for Health and Clinical Excellence - Advice

31. Comparative efficacy and safety of novel oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban) and warfarin among atrial fibrillation diagnosed patients: a network meta-analysis

Comparative efficacy and safety of novel oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban) and warfarin among atrial fibrillation diagnosed patients: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2016 PROSPERO

32. Dabigatran (Pradaxa) in deep vein thrombosis and pulmonary embolism

Dabigatran (Pradaxa) in deep vein thrombosis and pulmonary embolism Prescrire IN ENGLISH - Spotlight ''In the June issue of Prescrire International: Dabigatran (Pradaxa°) in deep vein thrombosis and pulmonary embolism'', 1 June 2015 {1} {1} {1} | | > > > In the June issue of Prescrire International: Dabigatran (Pradaxa°) in deep vein thrombosis and pulmonary embolism Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |  (...)  |   |   |   |   |  Spotlight In the June issue of Prescrire International: Dabigatran (Pradaxa°) in deep vein thrombosis and pulmonary embolism FREE DOWNLOAD In the New Products section of the June issue: compared with adjusted-dose warfarin, dabigatran provides no tangible advantages for patients with pulmonary embolism or deep vein thrombosis. Warfarin remains the standard drug. Full text available for free download. Summary The anticoagulant dabigatran

2015 Prescrire

33. Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran ? first line

Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran ? first line Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran – first line Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran – first line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSC. Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran – first line . Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2015 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Anticoagulants; Benzimidazoless; Blood Coagulation; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Thromboembolism Language Published English Country of organisation England English

2015 Health Technology Assessment (HTA) Database.

34. Dabigatran (Pradaxa)

Dabigatran (Pradaxa) © 2015 Thrombosis Canada Page 1 of 4 DABIGATRAN (PRADAXA ? ) OBJECTIVE: To provide an overview of the mechanism of action, licensed indications, dosing regimens, and side- effects of dabigatran. MECHANISM OF ACTION: Dabigatran is an oral direct thrombin (factor IIa) inhibitor. By binding reversibly to the active site of thrombin, dabigatran attenuates thrombin activity and reduces fibrin formation. INDICATIONS: Dabigatran is currently licensed in Canada for the following (...) impairment (creatinine clearance [CrCl] 30 to 50 mL/min). Dabigatran is contraindicated in patients with a CrCl <30 mL/min. c) Treatment of DVT and PE: Dabigatran 150 mg BID is started after 5 to 10 days of initial treatment with a parenteral anticoagulant. There is no recommended dose adjustment in patients with moderate renal impairment (CrCl 30 to 50 mL/min). The reduced dose of 110 mg has neverbeen evaluated in a VTE treatment clinical trial. ? Dabigatran should not be used in patients with a CrCl

2015 Thrombosis Interest Group of Canada

35. Praxbind (idarucizumab) - For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa?s blood-thinning effects

Praxbind (idarucizumab) - For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa?s blood-thinning effects Praxbind (idarucizumab) U.S. Department of Health and Human Services Search FDA Submit search Praxbind (idarucizumab) Vraylar (Cariprazine) Company: Boehringer Ingelheim Pharmaceuticals Application No.: 761025 Orig1 Approval Date: October 16, 2015 Persons with disabilities having problems accessing

2015 FDA - Drug Approval Package

36. Cohort study: Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin

Cohort study: Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin | BMJ Evidence (...) OR managers of institutional accounts Username * Password * your user name or password? You are here Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin Article Text Aetiology/Harm Cohort study Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin

2015 Evidence-Based Medicine

37. Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism Dabigatr Dabigatran ete an etexilate for the treatment xilate for the treatment and secondary pre and secondary prev vention of deep v ention of deep vein ein thrombosis and/or pulmonary embolism thrombosis and/or pulmonary embolism T echnology appraisal guidance Published: 17 December 2014 nice.org.uk/guidance/ta327 © NICE 2018. All rights reserved. Subject to Notice of rights (...) . They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

38. Bleeding events with dabigatran or warfarin in patients with venous thromboembolism (Abstract)

Bleeding events with dabigatran or warfarin in patients with venous thromboembolism Dabigatran was as effective as warfarin for the acute treatment of venous thromboembolism in the RE-COVER and RE-COVER II trials. We compared the incidence of bleeding with dabigatran versus warfarin in pooled data from these studies. The localisation, bleeding severity, and the impact of key factors on the incidence of bleeding, were compared between the dabigatran and warfarin treatment group. Altogether, 2553 (...) patients received dabigatran and 2554 warfarin, each for a mean of 164 days. The incidence of any bleeding event was significantly lower with dabigatran (hazard ratio [HR] 0.70; 95% confidence interval [CI], 0.61-0.79), as was the incidence of the composite of MBEs and clinically relevant non-major bleeding events (HR 0.62; 95% CI, 0.50-0.76). The incidence of major bleeding events (MBEs) was also significantly lower with dabigatran in the double-dummy phase (HR, 0.60; 95%CI, 0.36-0.99

2015 EvidenceUpdates Controlled trial quality: uncertain

39. Dabigatran (Pradaxa): life-threatening bleeding

Dabigatran (Pradaxa): life-threatening bleeding Prescrire IN ENGLISH - Spotlight: Archive ''Dabigatran (Pradaxa°): life-threatening bleeding'', 1 February 2013 {1} {1} {1} | | > > > Dabigatran (Pradaxa°): life-threatening bleeding Spotlight: Archives Every month, the subjects in Prescrire’s Spotlight. 2013 :  |   |  Spotlight Archives Dabigatran (Pradaxa°): life-threatening bleeding FEATURED REVIEW Dabigatran is an oral anticoagulant that inhibits thrombin but not vitamin K (...) . Pharmacovigilance studies have identified several situations in which patients have an increased risk of serious bleeding with dabigatran. Dabigatran should be reserved for patients at high risk of thrombosis in whom antivitamin K therapy poses difficult problems. Full review (3 pages) available for download by subscribers. Abstract Dabigatran (Pradaxa°) is an oral anticoagulant that inhibits thrombin but not vitamin K. In mid-2012, there was no commercial test to monitor its anticoagulant effect, nor

2014 Prescrire

40. Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience

Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience Prescrire IN ENGLISH - Spotlight ''Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience '', 1 June 2013 {1} {1} {1} | | > > > Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |    (...) |   |   |   |  Spotlight Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience FEATURED REVIEW Dabigatran, rivaroxaban and apixaban are oral anticoagulants used to prevent or treat thrombosis. Difficulties in the management of bleeding weigh heavily in the balance of potential harm versus potential benefit of these drugs. Full review (5 pages) available for download by subscribers. Abstract Dabigatran, rivaroxaban and apixaban

2014 Prescrire